• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Lyndra gets boost for drug delivery platform from U.S. allergy institute

May 2, 2017 By Sarah Faulkner

LyndraLyndra said today that it won a 5-year grant from the National Institute of Allergy and Infectious Diseases, a branch of the National Institutes of Health. The grant is slated to support the formulation and preclinical development of a once-weekly oral HIV treatment.

The Watertown, Mass.-based company makes use of a sustained-release technology developed by Robert Langer at the Massachusetts Institute of Technology. A star-shaped pill loaded with drugs remains in the gastric cavity after it’s been swallowed for a pre-determined length of time. After the drugs have been released, the pill splits into small pieces and safely passes through the GI tract, according to Lyndra.

The company said it plans to develop an antiretroviral therapy and pre-exposure prophylaxis that increases medication adherence and outcomes for patients with HIV, thanks to its newly-acquired funds from the NIAID.

“Given the need for life-long antiretroviral therapy, there is great interest in long-acting oral option to make it easier for patients to adhere to their treatment regimens,” Brigham & Women’s Hospital HIV specialist Dr. Paul Edward Sax said in prepared remarks.

“Inconsistent adherence to HIV therapies is particularly impactful due to the potential for therapeutic failure and the development of resistance. A patient forgetting to take his or her medication, even for a few days, has significant implications for long-term health. By creating a weekly oral formulation with an optimized pharmacokinetic profile, we believe we will enable improved therapeutic success. Oral long-acting therapies complement injectable therapies in development and potentially expand access,” chief scientific officer Andrew Bellinger added. “Support from NIAID will enable us to begin development of this important and timely therapeutic.”

In April, Lyndra closed a $23m Series A round, led by Polaris Partners, to fund the development of its long-acting therapeutic oral delivery platform. Quark Venture, GF Securities, Yonghua Capital, Healthlink Capital, Partners Healthcare, Suffolk Equity and others invested in the round.

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Research & Development Tagged With: lyndra, Massachusetts Institute of Technology, National Institutes of Health

IN CASE YOU MISSED IT

  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS